The article emphasizes that pharmaceutical companies should focus on their core mission of drug discovery and patient care, rather than developing AI systems. By purchasing specialized AI tools from vendors with industry knowledge, these companies can maintain control over their proprietary data while benefiting from advanced AI capabilities. The article concludes that partnering with external experts allows pharma companies to concentrate on their primary goals, accelerating innovation and ensuring effective use of resources.
Key takeaways:
- Pharmaceutical companies face a complex decision between building custom AI solutions in-house or buying them from external vendors, with considerations like cost, efficiency, and security playing crucial roles.
- Building AI systems internally can be challenging due to resource allocation, maintenance, and the need for specialized expertise, making it a potentially risky endeavor.
- Buying AI solutions offers advantages such as faster time to value, lower cost of ownership, and the ability to focus on core business innovation.
- Leveraging external AI expertise allows pharma companies to concentrate on their primary mission of drug discovery and patient care, enhancing their ability to deliver innovative medicines efficiently.